CannabisNewsBreaks

FridayMay 26, 2023 11:54 am

CannabisNewsBreaks – Bright Green Corporation (NASDAQ: BGXX) Announces Pricing of $3.5M Private Placement

Bright Green (NASDAQ: BGXX) is one of the few companies selected by the U.S. government to grow, manufacture and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export. The company recently announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 3,684,210 shares of common stock and warrants to purchase up to 3,684,210 shares of common stock, at a purchase price of $0.95 per share and accompanying warrant. Bright Green expects approximately $3.5 million in gross proceeds from the private placement. EF Hutton, division…

Continue Reading

ThursdayMay 25, 2023 1:14 pm

CannabisNewsBreaks – Jaxx Cannabis Owner, Veteran and Cannabis Advocate Featured in Recent Episode of The Plant Lady

Female empowerer and owner of Jaxx Cannabis, JM Balbuena, was featured in a recent episode of The Plant Lady podcast. JM joined host Jackie Bryant to discuss her wellness brand and dispensary’s humble beginnings in San Diego county, which wanted to scrub cannabis culture from its image, to the company’s success, which JM attributes much to patience and working for the system instead of against it. During the program, the host and guest “reminisce about the low-key dispensaries scattered around every neighborhood and the elaborate rouses needed as a front to keep them open like under-stocked coffee shops or deserted…

Continue Reading

ThursdayMay 25, 2023 12:59 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Plans to Participate in Virtual Investor Events Next Week

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, will be represented at two upcoming investor events. The company announced that members of its executive team will be participating in the Tribe Public Webinar, slated for May 31, 2023, and the Investor Summit, scheduled for June 1, 2023. According to the announcement, InMed CEO Eric A. Adams and BayMedica VP of sales and marketing Jerry Griffin will cohost a presentation for the Tribe Public Webinar. The virtual presentation, titled “Addressing the Increasing Demand for Rare Cannabinoids,” will begin at…

Continue Reading

TuesdayMay 23, 2023 3:20 pm

CannabisNewsBreaks – GRN Holding Corporation (GRNF), Marijuana Inc. Complete Merger, Positioning as Frontrunner in the Cannabis Industry

GRN Holding Corporation (OTC: GRNF) today announced successful completion of its merger with Marijuana Inc., solidifying a position as a dominant player in the cannabis industry. The milestone achievement marks a significant step forward in the shared vision of delivering high-quality cannabis products and driving innovation in the market. “We are delighted to announce the successful completion of the merger between GRN Holding Corporation and Marijuana Inc. This strategic consolidation positions us as a frontrunner in the cannabis industry, enabling us to provide exceptional products, expand market reach, and drive sustainable growth,” said GRNF CEO Donald Steinberg. “Together, we are…

Continue Reading

TuesdayMay 23, 2023 3:08 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Findings from DehydraTECH-CBD Hypertension Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced additional findings from last year’s human clinical study HYPER-H21-4. The findings demonstrate significant reductions in several pro-inflammatory biomarkers known to be linked to cardiovascular disease (“CVD”) and a host of other conditions. “There is some pre-clinical evidence for the anti-inflammatory actions of CBD, but this is likely the most convincing evidence in humans that I have ever seen,” said Dr. Philip Ainslie, cardiovascular advisor to Lexaria and lead investigator of the HYPER-H21-4 study. “The bigger picture is that inflammation is the key basis of atherosclerosis, and…

Continue Reading

FridayMay 19, 2023 12:45 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) CEO Featured in Upcoming Water Tower Research Fireside Chat

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, will be represented at an upcoming Water Tower Research Fireside Chat Series. The company announced that CEO Eric A. Adams will be the featured speaker at the May 23, 2023, fireside chat; the event is slated to begin at 1 p.m. ET. During the chat, Adams will present an overview of the company’s pharmaceutical development pipeline. He will also discuss subsidiary BayMedica and its anticipated impact on InMed's growth as well as upcoming catalysts for the company. A replay of the…

Continue Reading

ThursdayMay 18, 2023 2:49 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Study Demonstrates Significant Enhancement in Oral Estradiol Delivery

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced successful completion of its animal study HOR-A22-1, showing significant enhancement in the oral delivery of the estrogen hormone estradiol, an important component of therapeutic products in the women’s health sector. According to the update, the DehydraTECH-estradiol formulation achieved an average peak concentration in the bloodstream (or “Cmax”) of 5.65ng/mL, roughly nine times (900%) higher than that achieved with the control formulation at only 0.63 ng/mL. In addition, with estradiol known to be quickly converted into the metabolite estrone by cells in the uterus, mammary glands and…

Continue Reading

WednesdayMay 17, 2023 11:55 am

CannabisNewsBreaks – ECGI Holdings Inc. (ECGI) Reports 1,000% Annualized Distribution Channel Growth for New Cannabis Brand

ECGI Holdings (OTC: ECGI), D/B/A Elite Cannabis Group Incorporated, a Nevada -based portfolio company pivoting into the legal cannabis and cannabinoid marketplace, has announced that 8bit, its soon soon-to-be-acquired cannabis brand, is experiencing significant growth. The company noted that 8bit has expanded its active distribution footprint by 30 locations, increasing from 20 stores to 50 stores in just a few weeks. ECGI reports that is a 150% increase in distribution footprint in less than two months, which tops 1,000% annualized growth in distribution footprint over the same period. In March, ECGI entered a binding letter of intent to acquire the key personnel,…

Continue Reading

TuesdayMay 16, 2023 3:03 pm

CannabisNewsBreaks – AmeriCann Inc. (ACAN) Reports Best-Ever Revenue, Net Income

AmeriCann (OTCQB: ACAN), a cannabis company that develops state-of-the-art cultivation, product manufacturing and distribution facilities, is reporting on its financial and operational results for the quarter ending March 2023; the report showed the company’s best-ever annual revenue and net income for its latest four quarters. According to the report, AmeriCann has reported five consecutive quarters of positive net income, with net income increasing 257% and revenue increasing an estimated 12% for the quarter ended March 2023 compared to the quarter ended March 2022. In the report, the company attributed the increased revenue to products produced and manufactured at the company's…

Continue Reading

MondayMay 15, 2023 3:34 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Q3 2023 Financial Results, Provides Business Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced financial results for the third quarter of the fiscal year 2023, which ended March 31, 2023. “The third quarter of fiscal year 2023 was an important period for InMed, as we achieved several key milestones across our different business segments, including completing enrollment in our phase 2 clinical trial for epidermolysis bullosa, marking the first time cannabinol (‘CBN’) has completed a phase 2 clinical trial. We look forward to the data read out during 3Q and will then…

Continue Reading